Procter & Gamble, Cosmital SA, CH-1723 Marly, Switzerland.
Mutat Res. 2009 Nov-Dec;680(1-2):31-42. doi: 10.1016/j.mrgentox.2009.09.002. Epub 2009 Sep 16.
In vivo genetic toxicology tests measure direct DNA damage or the formation of gene or chromosomal mutations, and are used to predict the mutagenic and carcinogenic potential of compounds for regulatory purposes and/or to follow-up positive results from in vitro testing. These tests are widely used and consume large numbers of animals, with a foreseeable marked increase as a result of the EU chemicals legislation (REACH), which may require follow-up of any positive outcome in the in vitro standard battery with appropriate in vivo tests, regardless of the tonnage level of the chemical. A 2-day workshop with genotoxicity experts from academia, regulatory agencies and industry was hosted by the European Centre for the Validation of Alternative Methods (ECVAM) in Ranco, Italy from 24 to 25 June 2008. The objectives of the workshop were to discuss how to reduce the number of animals in standard genotoxicity tests, whether the application of smarter test strategies can lead to lower animal numbers, and how the possibilities for reduction can be promoted and implemented. The workshop agreed that there are many reduction options available that are scientifically credible and therefore ready for use. Most of these are compliant with regulatory guidelines, i.e. the use of one sex only, one administration and two sampling times versus two or three administrations and one sampling time for micronucleus (MN), chromosomal aberration (CA) and Comet assays; and the integration of the MN endpoint into repeat-dose toxicity studies. The omission of a concurrent positive control in routine CA and MN tests has been proven to be scientifically acceptable, although the OECD guidelines still require this; also the combination of acute MN and Comet assay studies are compliant with guidelines, except for sampling times. Based on the data presented at the workshop, the participants concluded that these options have not been sufficiently utilized to date. Key factors for this seem to be the uncertainty regarding regulatory compliance/acceptance, lack of awareness, and an in many cases unjustified uncertainty regarding the scientific acceptance of reduction options. The workshop therefore encourages the use and promotion of these options as well as the dissemination of data related to reduction opportunities by the scientific community in order to boost the acceptance level of these approaches. Furthermore, experimental proof is needed and under way to demonstrate the credibility of additional options for reduction of the number of animals, such as the integration of the Comet assay into repeat-dose toxicity studies.
体内遗传毒性试验测量直接的 DNA 损伤或基因或染色体突变的形成,并用于预测化合物的致突变性和致癌性潜力,以进行监管目的和/或对体外测试的阳性结果进行后续跟踪。这些测试被广泛应用,并消耗大量的动物,由于欧盟化学品法规(REACH),预计这种情况会明显增加,这可能需要对体外标准电池中的任何阳性结果进行后续的适当体内试验,无论化学品的吨位水平如何。2008 年 6 月 24 日至 25 日,欧洲替代方法验证中心(ECVAM)在意大利兰科举办了一次为期两天的学术、监管机构和行业遗传毒性专家研讨会。研讨会的目的是讨论如何减少标准遗传毒性试验中的动物数量,应用更智能的试验策略是否可以减少动物数量,以及如何促进和实施减少的可能性。研讨会一致认为,有许多减少的选择是科学可信的,因此可以使用。其中大多数符合监管指南,即使用仅一种性别、一种给药和两次取样时间,而不是微核(MN)、染色体畸变(CA)和彗星试验的两种或三种给药和一次取样时间;以及将 MN 终点纳入重复剂量毒性研究。已经证明,在常规 CA 和 MN 试验中省略同时进行的阳性对照在科学上是可以接受的,尽管 OECD 指南仍然需要这一点;急性 MN 和彗星试验研究的组合也符合指南,除了取样时间。根据研讨会提出的数据,与会者得出结论,迄今为止,这些选择尚未得到充分利用。造成这种情况的关键因素似乎是对监管合规性/可接受性的不确定性、缺乏认识,以及在许多情况下对减少选择的科学接受性的不合理不确定性。因此,研讨会鼓励科学界使用和推广这些选择,并传播与减少机会相关的数据,以提高这些方法的接受程度。此外,还需要并正在进行实验证明,以证明减少动物数量的其他选择的可信度,例如将彗星试验纳入重复剂量毒性研究。